Boehringer Bids To Go Beyond Slowing IPF

Promising Phase II Data In Lung Disease With High Mortality

 
• By Kevin Grogan
  
Boehringer Ingelheim headquarters in Ingelheim, Germany
• Source: Boehringer Ingelheim (dieth+schröder-fotografie)

More from Respiratory

More from Therapy Areas